drugset / Trial / NCT01787331

Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer

NCT01787331

Phase 2 Completed 21 enrolled University of California, San Francisco
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well itraconazole works in treating patients with biochemically relapsed prostate cancer. Itraconazole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2013-10-29
Primary completion
2017-05-30
Completion
2018-09-30

Publications

  • Results Mina Lee, Haemin Hong, Won Kim, Terence W. Friedlander, Lawrence Fong, Amy M. Lin, Eric Jay Small, Mallika Sachdev Dhawan, Xiao X. Wei, Tammy J. Rodvelt, Brigid Miralda, Charles J. Ryan, and Rahul Raj Aggarwal.A phase II study of itraconazole in biochemically recurrent prostate cancer. Journal of Clinical Oncology 2018 36:6_suppl, 362-362

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 300 mg Oral